203 related articles for article (PubMed ID: 8603002)
1. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group.
Pulkki K; Pelliniemi TT; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Br J Haematol; 1996 Feb; 92(2):370-4. PubMed ID: 8603002
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma.
Kyrtsonis MC; Dedoussis G; Zervas C; Perifanis V; Baxevanis C; Stamatelou M; Maniatis A
Br J Haematol; 1996 May; 93(2):398-400. PubMed ID: 8639436
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma.
Stasi R; Brunetti M; Parma A; Di Giulio C; Terzoli E; Pagano A
Cancer; 1998 May; 82(10):1860-6. PubMed ID: 9587117
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias.
Ohtani K; Ninomiya H; Hasegawa Y; Kobayashi T; Kojima H; Nagasawa T; Abe T
Br J Haematol; 1995 Sep; 91(1):116-20. PubMed ID: 7577617
[TBL] [Abstract][Full Text] [Related]
6. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in multiple myeloma.
Kyle RA
Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
[TBL] [Abstract][Full Text] [Related]
8. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
Wierzbowska A; Urbańska-Ryś H; Robak T
Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
[TBL] [Abstract][Full Text] [Related]
9. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
10. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors.
Turesson I; Abildgaard N; Ahlgren T; Dahl I; Holmberg E; Hjorth M; Nielsen JL; Odén A; Seidel C; Waage A; Westin J; Wislöff F
Br J Haematol; 1999 Sep; 106(4):1005-12. PubMed ID: 10520004
[TBL] [Abstract][Full Text] [Related]
11. Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation.
Toren A; Novick D; Or R; Ackerstein A; Slavin S; Nagler A
Transplantation; 1996 Jul; 62(1):138-42. PubMed ID: 8693533
[TBL] [Abstract][Full Text] [Related]
12. IL-6 and soluble IL-6 receptor levels change differently after surgery both in the blood and in the operative field.
Hisano S; Sakamoto K; Ishiko T; Kamohara H; Ogawa M
Cytokine; 1997 Jun; 9(6):447-52. PubMed ID: 9199879
[TBL] [Abstract][Full Text] [Related]
13. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.
Salvi M; Girasole G; Pedrazzoni M; Passeri M; Giuliani N; Minelli R; Braverman LE; Roti E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2976-9. PubMed ID: 8768861
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H; Robak E
Mediators Inflamm; 1998; 7(5):347-53. PubMed ID: 9883970
[TBL] [Abstract][Full Text] [Related]
15. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.
Tsirakis G; Pappa CA; Kaparou M; Boula A; Katsomitrou V; Xekalou A; Kyriakaki S; Alexandrakis MG
Tumour Biol; 2013 Apr; 34(2):859-64. PubMed ID: 23242610
[TBL] [Abstract][Full Text] [Related]
16. Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein.
Kyriakou D; Papadaki H; Eliopoulos AG; Foudoulakis A; Alexandrakis M; Eliopoulos GD
Int J Hematol; 1997 Oct; 66(3):367-71. PubMed ID: 9401283
[TBL] [Abstract][Full Text] [Related]
17. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
Kotake S; Sato K; Kim KJ; Takahashi N; Udagawa N; Nakamura I; Yamaguchi A; Kishimoto T; Suda T; Kashiwazaki S
J Bone Miner Res; 1996 Jan; 11(1):88-95. PubMed ID: 8770701
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
20. Serum Levels of Interleukin-8 and Soluble Interleukin-6 Receptor in Patients with Stage-I Multiple Myeloma: A Case-Control Study.
Kohsari M; Khadem-Ansari MH; Rasmi Y; Sayyadi H
Asian Pac J Cancer Prev; 2020 Jan; 21(1):127-132. PubMed ID: 31983174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
